Antibody–biopolymer conjugates in oncology: a review

[thumbnail of molecules-28-02605.pdf]
molecules-28-02605.pdf - Published Version (835kB) | Preview
Available under license: Creative Commons Attribution

Chavda, Vivek P ORCID: 0000-0002-7701-8597, Balar, Pankti C ORCID: 0000-0002-5718-669X, Teli, Divya, Davidson, Majid ORCID: 0000-0002-3241-6444, Bojarska, Joanna ORCID: 0000-0001-9190-6913 and Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771 (2023) Antibody–biopolymer conjugates in oncology: a review. Molecules, 28 (6). ISSN 1420-3049


Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery. Although being well-accepted, they have many lacunas in the form of severe side effect resulting from lack of targeted delivery. Antibody biopolymer conjugates are a novel method which is an add-on to older methods of immunization. It is used in various diseases and disorders. It ensures the targeted delivery of molecules to increase its efficacy and reduce unwanted effects of the molecule/drug to normal cells. It shows miraculous results in the treatment and management of several cancers even in advanced stages. Herein, we present the chemistry between biopolymer and antibody, their effects on cancer as well as the basic differences between antibody–drug conjugates and antibody–biopolymer conjugates.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.3390/molecules28062605
Official URL
Subjects Current > FOR (2020) Classification > 3204 Immunology
Current > Division/Research > Australian Institute of Musculoskeletal Science (AIMSS)
Current > Division/Research > Institute for Health and Sport
Keywords cancer, oncology, cancer treatment, antibody biopolymer, immunisation
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login